Ads
related to: wet macular degeneration injections available in california
Search results
Results From The WOW.Com Content Network
Pegaptanib [2] sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). [3] It was discovered by NeXstar Pharmaceuticals (which merged with Gilead Sciences in 1999) and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States.
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, [2] is a publicly traded [3] clinical stage gene therapy company located in Redwood City, California. [4] The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD). [5]
In October 2019, Novartis announced that the US Food and Drug Administration (FDA) approved brolucizumab injection for the treatment of wet age-related macular degeneration. [7] The FDA approved brolucizumab based on evidence from two clinical trials (Trial 1/ NCT02307682 and Trial 2/NCT02434328) of 1459 participants, 50–97 years old, with ...
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab.It is an anti-angiogenic [16] that is approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion.
In some cases, dry macular degeneration can convert to “wet” degeneration, caused by “bleeding or a leaky blood vessel,” that leads to a much more rapid loss of visual acuity, explains ...
Aflibercept, sold under the brand names Eylea and Zaltrap among others, is a medication used to treat wet macular degeneration and metastatic colorectal cancer. [16] [17] It was developed by Regeneron Pharmaceuticals.